Kornimate/medical-research-clean huggingface dataset:
efficiency of shock-wave therapy in symptomatic hip osteoarthritis

Conditions: Hip Osteoarthritis

Summary: the objectives of treatment in hip osteoarthritis are pain relief, improve joint range of motion and muscle force, gait rehabilitation, patient education and socio-professional reintegration.the non-pharmacological and non-surgical methods include certain types of physical therapy: massage, heat, ultrasound, laser, shockwave therapy. few studies have been conducted so far for outcome measurement in symptomatic hip osteoarthritis.

the objectives of treatment in hip osteoarthritis are pain relief, improve joint range of motion and muscle force, gait rehabilitation, patient education and socio-professional reintegration.the non-pharmacological and non-surgical methods include certain types of physical therapy: massage, heat, ultrasound, laser, shockwave therapy. among them, shockwave therapy is not a new treatment method, and seems to be effective in rotator cuff pathology, tennis elbow, and also on knee osteoarthritis, but few studies have been conducted so far for outcome measurement in symptomatic hip osteoarthritis.

Eligibility criteria:
inclusion criteria: * unilateral or bilateral hip osteoarthritis exclusion criteria: * other disorders that are contraindications for shockwave or ultrasound application
cell phone application for vision assessment

Conditions: Visual Impairment

Summary: the purpose of this study is to evaluate how visual acuity assessed with peek acuity (a cell phone application to check visual acuity) among preschool and school-aged children 3 to less than18 years of age (1) compares to the standard visual acuity exam in the ophthalmology clinic and (2) performs as a screening test for ocular abnormalities that warrant referral for an eye exam.

current recommendations suggest that children begin visual acuity screening as early as possible with most children capable at 3 years old though some may not be able to cooperate until 4 years of age. while visual acuity screening is standard in schools and pediatric clinics, the specificity of the exams has been questioned. a number of community screening exams rely on outdated and flawed methods that may not accurately access the vision of all children. because many children who fail these vision screenings are referred to ophthalmology clinics without a true visual acuity deficit, a more accurate but accessible, cost effective, and feasible vision screening exam is necessary. one solution is a smart phone application designed to assess visual acuity, called peek acuity. the application is available for android operating system and can be downloaded as a free beta from the google play store. a short tutorial walks users through the application. the application displays a single letter "e" in 4 positions, 0, 90, 180, and 270 degrees (rolling "e") that does not require english comprehension. patients are instructed to point in the direction of the arms of the "e." the examiner records the responses by swiping the screen in the direction the patient points. the application uses responses to calculate visual acuity and typical exams can be completed within 2 minutes. in one study, peek acuity visual assessments have been shown to be comparable to that determined by the ophthalmology clinic in patients aged 55 years and older. this study also found that the peek acuity is efficient, with an average exam time of 77 seconds compared to 82 seconds using the standard snellen eye chart.

Eligibility criteria:
inclusion criteria: * capable and willing to provide consent * 3 to less than 18 years of age exclusion criteria: * unable or unwilling to give consent * over 18 years of age * less than 3 years of age

Keywords: screening cell phone application
effects of the visual stimulation on the motor and visual cortex in migraneurs with and without aura

Conditions: Migraine Disorders

Summary: the aim of this study is to investigate the motor and visual cortex excitability in response to visual stimulation of migraineurs with and without aura compared to healthy individuals. for this purpose, electrical cortical activity of migraineurs will be compared to healthy volunteers.

a cross sectional study to compare the best approach to migraineurs evaluation. for this, healthy individuals, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological endpoints and thus compare with those obtained in individuals with migraineurs volunteers. all volunteers (healthy and migraineurs) will be submitted to a neurophysiological evaluation through transcranial magnetic stimulation (tms) and electroencephalography (eeg). a visual stimulation will be delivered during the assessment of habituation through visual evoked potential volunteers (vep-habituation) and the following measures will be evaluated before and after visual stimulation: (i) motor evoked potentials (mep); (ii) motor threshold (mt); (iii) short interval cortical inhibition (sici); (iv) intracortical facilitation (lcf) and (v) phosphene threshold (pt).

Eligibility criteria:
inclusion criteria: * ages: 18-55 years * gender: both * prior headache report exclusion criteria: * pregnant women; * pacemaker; * history of seizures; * metallic implants in the head; * patients with clinical evidence of brain injuries; * chronic pain associated to others diseases; * use of neuroleptic medications

Keywords: migraine disorders cortical excitability transcranial magnetic stimulation electroencephalography
trial of adjuvant chemotherapy for gastric cancer

Conditions: Stomach Cancer

Summary: this study is designed to evaluate the efficacy of the intraperitoneal chemotherapy with early mitomycin administration and adding cisplatin to prolonged treatment with doxifluridine compared to mitomycin plus doxifluridine in resected advanced gastric cancer.

stomach cancer is the most common cancer in korea and one of the major health problems worldwide. the most effective treatment for gastric cancer is curative surgical resection of primary tumor. however, a substantial number of patients eventually die of recurrences after curative resection. a number of randomized trials investigating the role of adjuvant chemotherapy have been conducted. however, the efficacy of adjuvant chemotherapy is still controversial and varied between western and asian trials. meta-analysis of western trials didn't demonstrate the benefit of adjuvant chemotherapy after curative resection. conversely, some asian studies have demonstrated the efficacy of adjuvant chemotherapy after curative resection. in a previous study, mitomycin plus tegafur prolonged the survival in resected gastric cancer compared to no treatment. this study is designed to evaluate the efficacy of the intraperitoneal chemotherapy with early mitomycin administration and adding cisplatin to prolonged treatment with doxifluridine compared to mitomycin plus doxifluridine.

Eligibility criteria:
inclusion criteria: * pathologically proven gastric adenocarcinoma * grossly serosa invasion of primary tumor is suspicious * curative resection was done * stage ii, iiia, iiib, iv (including t4, lesions or n3, but excluding m1 lymph node metastasis) * age: 18-69 years old * performance status: eastern cooperative oncology group (ecog) 0-2 * adequate bone marrow function (white blood cell counts ≥ 4,000/ul, platelet count ≥ 100,000/ul, hemoglobin ≥ 10 g/dl) * adequate renal function (serum creatinine≤ 1.5) * adequate liver function (serum bilirubin ≤1.5 mg/dl, aspartate aminotransferase (ast)/alanine aminotransferase (alt) ≤ 3 x normal upper limit) * written informed consent was signed by the patient exclusion criteria: * previous chemotherapy or radiotherapy * active ongoing infection which antibiotic treatment is needed * pregnant or lactating women * psychosis or convulsion disorder * ascites in preoperative abdomen computed tomography (ct) * systemic disease which interfere the administration of chemotherapy * postoperative pathologic stage ia, ib * postoperative pathology indicates that resection margin is involved * previous history of other malignancy except cured non-malignant skin cancer and uterine cervical cancer in situ

Keywords: stomach cancer adjuvant chemotherapy mitomycin cisplatin doxifluridine
open-label extension study of mcs-2 in the treatment of lower urinary tract symptoms (mcs-2-us-c)

Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia

Summary: this is an open-label extension study of another study protocol, mcs-2-us-a. subjects who have completed the 12-week treatment and procedures under the protocol mcs-2-us-a will be eligible for this study.

this open-label extension study is designed to further assess the long-term safety and efficacy of mcs-2. subjects who have completed the 12-week treatment and procedures under the protocol mcs-2-twn-a will be eligible for another 40 weeks of mcs-2 treatment at the optimal dose selected after the phase 2b part of mcs-2-us-a. subjects are limited to those who are currently not being treated medically for bph or luts.

Eligibility criteria:
inclusion criteria: * subject has completed 12 weeks of treatment under the protocol mcs-2-us-a. * subject is able to understand and willing to conform to the study procedures and has signed the informed consent form for participation in this extension study. exclusion criteria: * subject has severe luts at the last visit under the protocol mcs-2-us-a. * subject is considered ineligible for the study by the investigator(s).

Keywords: benign prostatic hyperplasia mcs-2 multi-carotenoids lower urinary tract symptoms international prostate symptom score
a master protocol for orforglipron (ly3502970) in participants with hypertension and obesity or overweight: (attain-hypertension screening)

Conditions: Hypertension

Summary: the gzpl master protocol will support 2 independent studies, j2a-mc-gzl1 (gzl1) and j2a-mc-gzl2 (gzl2). the purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.


Eligibility criteria:
inclusion criteria: * has systolic blood pressure (sbp) ≥ 140 mmhg and/or diastolic blood pressure (dbp) ≥ 90 mmhg (if dbp criteria alone is met, sbp must be ≥130 mmhg) at screening (visit 1). * has sbp ≥ 140 mmhg and/or dbp ≥ 90 mmhg (if dbp criteria alone is met, sbp must be ≥130 mmhg) at week 0 (visit 3). * untreated for hypertension, or on stable antihypertensive medications ≥ 30 days prior to visit 1. * have a body mass index (bmi) ≥ 25 kg/m². exclusion criteria: * has sbp ≥170 mmhg and/or dbp ≥110 mmhg at visit 1 or at visit 3. * has known secondary causes of hypertension * have heart failure with reduced ejection fraction (hfref) diagnosis * have had any of the following conditions within 90 days prior to screening. * hospitalization for hypertension or for congestive heart failure * acute coronary syndrome or acute myocardial infarction, or * cerebrovascular accident (stroke). * have type 1 diabetes (t1d) * have acute or chronic hepatitis, including a history of autoimmune hepatitis
efficacy of compound betamethasone injection combined with ropivacaine in ultrasound-guided intercostal nerve block for chronic post-thoracotomy pain

Conditions: Nerve Block

Summary: the patients were divided into two groups by random number method: grouprd1 group and grouprd2 group were given general anesthesia and intercostal nerve block.the drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml.

the rd1 group received ultrasound-guided intercostal nerve block at the incision before anesthesia induction, and the rd2 group received ultrasound-guided intercostal nerve block at the lateral costal angle before anesthesia induction.

Eligibility criteria:
inclusion criteria: 1. 18-70 years old 2. asa grade i-iii 3. bmi: 18.5-28kg/m2 4. type of surgery: elective thoracoscopic lung mass resection 5. informed consent has been signed by the patient and/or family members exclusion criteria: 1. game anesthesia or sugar cortical hormone drugs allergic 2. preoperative use of opioid medicines 3. serious blood coagulation dysfunction 4. serious heart, lung, liver and renal insufficiency 5. put, chemotherapy, and glucocorticoid immunosuppressive therapy history or diseases of the immune system 6. peptic ulcer 7. newly gastrointestinal surgery 8. has a history of thoracic surgery 9. is the central nervous system disease 10. other glucocorticoids should be used with caution in patients such as fractures, wound repair, corneal ulcers, hyperadrenocortical disease, diabetes mellitus, pregnant women, etc.
immune response to influenza vaccine in esrd patients

Conditions: Immunology; Nephrology

Summary: on-line hemodiafiltration (hdf) clears more azotaemic toxins compared to high-flux hemodialysis (hd). the response to vaccination is impaired in dialysis patients. we aimed to study the immune responses to influenza vaccine in dialysis patients treated by hdf vs. hd.


Eligibility criteria:
inclusion criteria: - esrd patients aged 18 years or older, who had been treated for more than one month of either thrice weekly on-line hemodiafiltration (hdf) or conventional high flux hemodialysis (hd), with a session dialyzer urea clearance (kt/v urea) of 1.2 and greater, with a convection volume target of 20 l/session for the hdf group exclusion criteria: * had received any vaccination within the previous four weeks, or influenza vaccination within six months * patient who reported upper respiratory tract symptoms within three days prior to the study vaccination * a history of allergy to influenza vaccine or egg * thrombocytopenia * in receipt of immunosuppressant medications, chemotherapy, or had immunodeficiency

Keywords: esrd hemodialysis hemodiafiltration influenza vaccine immune response
treatment of patients suffering from nervous restlessness with pascoflair®

Conditions: Nervous Restlessness

Summary: the study was carried out as a prospective, non-interventional study with the intention of subsequent process cost analyses (pca) and also considers quality of life, drug misuse, dependence, adverse events and therapy satisfaction.

the study was carried out as a prospective, non-interventional study with the intention of subsequent process cost analyses (pca) and also considers quality of life, drug misuse, dependence, adverse events and therapy satisfaction. data were collected in collaboration with 22 physicians in germany. the study was designed as a one armed non-interventional study. patients had to suffer from nervous restlessness in order to be eligible for study documentation. participants agreed to a medical treatment with pascoflair® of 12 weeks. in this context, documented patients could take pascoflair® at the first time or could have started within the past three months before the initial visit. furthermore, documented patients had to be older than 18 years and must be able to read and understand the patient declaration of data protection and the declaration of consent. the patient must not be an alcoholic, must not be drug dependent and have no other types of addiction. patients who were pregnant or breast-feeding were not eligible for study participation. furthermore, patients showing hypersensitivity against passionflower extract or against other components of the medication were excluded. the signed declaration of consent of participating patients is available. the treatment of affected patients may not be documented, if a redemption (written or spoken) of the declaration of consent is existing or the patient takes benzodiazepines.

Eligibility criteria:
inclusion criteria: * patients suffering from nervous restlessness exclusion criteria: * age \< 18 years and must be able to read and understand the patient declaration of data protection and the declaration of consent * alcoholics, drug pending, addictive disorder * pregnancy or lactating * patients showing hypersensitivity against passionflower extract or against other components of the medication

Keywords: nervous restlessness pascoflair passiflora incarnata benzodiazepine
novel method to diagnose acute myocardial ischemia

Conditions: Myocardial Infarction; Angina, Unstable; Myocardial Ischemia; Coronary Disease

Summary: the aim of this study is to improve the detection of heart attack in people who come to a hospital emergency room (er) with cardiac symptoms. we are testing a novel technology that calculates the heart's electrical activity at points all around the upper body torso and develops a map showing areas indicating heart attack. our hypothesis is that this new body mapping technique will be better than the standard electrocardiogram (ecg) in detecting heart attack.

the overall aims of the proposed research are (1) to improve the ecg diagnosis of patients who present to the er with heart attack and (2) to improve the monitoring of recurrent heart attack in these patients while they are being treated in the hospital. the proposed research will test a promising new technique, termed estimated body surface potential mapping. this novel method involves estimating ecg information across the entire upper body from 10 electrodes placed in strategic positions. in patients who come to the er complaining of chest pain, shortness of breath or some other symptom of a heart attack, we will: (1) record continuous, 24 hour, standard ecgs (usual, current method used) and at the same time (2)record continuous 24 hour experimental recordings from which a body surface map will be calculated. two experts who do not know whether the patient actually had a heart attack or not will analyze these 2 methods for signs of heart attack. we expect that more correct diagnoses will happen with the new experimental body mapping technique. the correct diagnosis will be based upon a blood test which is considered the best test to prove there is heart damage. the blood test does not become abnormal until hours after the attack, however, so the ecg diagnosis must be made and treatment initiated before results of the blood test are available. if the expected diagnostic improvements are confirmed in this study, the long term benefit would be more accurate er decision-making of patients with heart attack and more timely treatment. the benefits of more timely and definitive treatment would be an improvement in long-term survival, functional status, and quality of life in patients treated for heart attack. we plan to enroll 1,320 patients who present to the er at the university of california, san franicsco to participate in the study. we will follow these patients for a year following their er visit to determine whether they survived and which ecg method predicted death more accurately.

Eligibility criteria:
inclusion criteria: * all individuals who present to the ucsf emergency room between 7 am and 7 pm, monday through friday, who have symptoms of myocardial infarction. exclusion criteria: * patients with left bundle branch block or ventricular pacemaker rhythm

Keywords: myocardial infarction electrocardiography myocardial ischemia emergency medicine monitoring, physiologic
study of the treatment of burn wounds with antimicrobial topical soaks

Conditions: Burn

Summary: determine effectiveness of various antimicrobial solutions on burn wounds (infections, wound healing, length of hospital stay).

patients were treated with both sulfamylon soaks and silver nitrate soaks on different burn areas. these two areas were then compared for incidence (percentage) of infections.

Eligibility criteria:
inclusion criteria: * burn injury requiring excisional therapy * hospitalization required until wounds are closed exclusion criteria: * known hypersensitivity to products * outpatient treatment for burn injury

Keywords: burn wounds wound infection topical antimicrobials cerium dakins sulfamylon soaks silver nitrate
ramosetron pre-treatment for ponv and qt prolongation

Conditions: PONV; Prolonged QTc Interval

Summary: ramosetron is commonly used to prevent postoperative nausea and vomiting (ponv) in the eastern asia. the prolongation of qtc interval is a main side effect. in this study, the pre-treatment time of ramosetron to decrease ponv, and qtc prolongation is compared.

this prospective study evaluate 42 female patients who underwent laparoscopic gynecologic surgery under general anesthesia. group i (n=21) receive 0.6mg of ramosetron at anesthesia induction. group r (n=21) received the same at the end of surgery. ponv is evaluated at arrival to post-anesthetic care unit (pacu), before induction, discharge from pacu, 24-, 48-, and 72- after discharge from pacu. the qtc interval is checked before anesthesia, at arrival to pacu, and 24-h after discharge from pacu. forty two subjects are needed with an α value of 0.05, a power of 0.8, and effect size difference of 0.9.

Eligibility criteria:
inclusion criteria: * patients who underwent laparoscopic gynecologic surgery exclusion criteria: * preoperative bradyarrhythmia in ecg

Keywords: ramosetron
genetic fronto temporal dementia initiative in lille

Conditions: Frontotemporal Dementia

Summary: genfi lille is a french cohort that belongs to the international initiative genfi2, a five year longitudinal biomarker cohort study of genetic ftd and its associated disorders (including mnd/als) investigating members of families with a known mutation in grn or mapt or an expansion in c9orf72 (including those affected with the disorder as well as at-risk members of families).

the purposes of this study is : * to improve characterization of symptomatic ftd patients or presymptomatic subjects at risk of genetic ftd * to develop markers indicative of the optimal time to start disease-modifying therapy, based on the proximity to clinical onset. * to develop markers of disease progression that can be used as outcome measures. * to derive sample size estimates for clinical trials. participants will include those affected with the disorder as well as at-risk members of families (both mutation carriers and non-carrier first-degree relatives who will serve as a control group). all participants will be assessed longitudinally with a set of clinical, neuropsychiatric, cognitive, imaging and biosample protocols.

Eligibility criteria:
inclusion criteria: * the participant must be 18 years old or older. * the participant must be a member of a family with a known pathogenic mutation in the grn or mapt genes, or with a pathogenic expansion in the c9orf72 gene : * an affected member is one who has been clinically diagnosed by a neurologist as having frontotemporal dementia or a disorder in the ftd spectrum. * an at-risk member is one who is a first-degree relative of a family member affected with the disease. * pathogenicity of a grn or mapt mutation is defined by those included within the genfi list of ftd mutation. if a novel mutation is discovered that is likely to be pathogenic and has not yet been included within the ftd mutation database then the genfi genetics core will decide on inclusion. please send an email to the genfi trials team at genfi@ucl.ac.uk. * a pathogenic c9orf72 expansion is defined as greater than 30 repeats. intermediate expansions are not considered pathogenic. * participants from one of the small number of families around the world in which 2 (or more) pathogenic mutations have been found should not be included in genfi. * if the participant is demented or cognitively impaired there must be an available caregiver that can escort them. * the participant must have an identified informant. * the participant must be fluent in the language of their country of assessment. * the participant accepts that genetic analysis will be carried out on his/her blood samples, and that no results will be available neither for the investigator nor for the participant. exclusion criteria: * participant has another medical or psychiatric illness that would interfere in completing assessments. * contraindications to fdg-pet (allergy to fdg...) * participant is pregnant.

Keywords: frontotemporal dementia biomarker social cognition genetic mutation